The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10509 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of schizophrenia. The specific indication will be determined after the completion of clinical research.